Antipsychotic Medications in Parkinson's Disease Psychosis; A Systematic Review of Double-Blind, Randomised, Placebo-Controlled Trials - PubMed
3 hours ago
- #Parkinson's disease
- #psychosis
- #antipsychotics
- Psychosis is a common symptom in Parkinson's disease (PD), affecting up to 75% of patients over time.
- Parkinson's disease psychosis (PDP) leads to increased morbidity, caregiver burden, and higher mortality risk.
- Up to 35% of PD patients are prescribed antipsychotics (APs) within 7 years of diagnosis.
- A systematic review analyzed 11 double-blind, randomized, placebo-controlled trials on APs for PDP.
- Quetiapine and olanzapine showed no significant improvement in PDP symptoms, with olanzapine worsening motor symptoms.
- Clozapine significantly improved psychosis with large effect sizes but has significant side-effects.
- Pimavanserin also showed significant improvement in PDP symptoms without worsening motor function.
- The review suggests quetiapine may not be evidence-based for PDP, while clozapine is effective but limited by side-effects.